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T-cell imbalance. In accordance with the decrease of Th1 CD41 T
cells in the PB of CR patients, we observed a valuable decrease of
IFNg plasma concentrations, which reached the levels typical of
HD. Contrary to CR patients, in PR patients we observed a transient
decrease of GVHD plasmatic markers and Th1/Treg, Th17/Treg
ratios, while NR patients showed stable or even increasing levels of
all analysed plasmatic and cellular markers.
In summary, despite its limited size, the present study suggests
that MSCs, upon infusion, are able to convert an inflammatory envi-
ronment to a more physiological one, both at a cellular level, pro-
moting the expansion of circulating Tregs, and at a molecular
level, diminishing inflammatory cytokines.31
PROGNOSTIC FACTORS IN ALLOGENEIC HEMATOPOIETIC CELL TRANS-
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GvHD is a major problem in allogeneic hematopoietic cell trans-
plantation (HCT) fom unrelated donors (UD). In our prospective
randomized multicenter trial we could show the efficacy of addi-
tional ATG-F to standard GvHD prophylaxis with cyclosporine A
and Mtx in reducing all grades of acute and chronic GvHD without
negatively affecting NRM, relapse rate or DFS in 201 adult patients
(median age 40 (range 18-60) years) with leukemia or MDS in early
(n 5 107) and advanced (n 5 94) disease transplanted after myeloa-
blative conditioningwithmarrow (n5 37) or blood (n5 134). (Finke
et al., Lancet Oncol, 2009).
Risk factors for the outcome after UD-HCT have been postulated
from retrospective analyses of registry data, however data from ran-
domized trials are lacking.With an extended follow of median 3 years
we present mature data on outcome and multivariate analysis of risk
factors: Incidence of grade III-IV aGvHD was 11.7% in the ATG-F
group and 25.5% in the control group (p 5 0.039), the incidence of
extensive chronicGvHD (cGvHD) after three years was 12.2% versus
45.0% (p\0.0001),DFSwas 48.0%and 38.4%, (p5 0.71), incidence
of relapse was 32.6% and 28.2% (p 5 0.47), incidence of NRM was
19.4% and 33.5% (p 5 0.18), and OS was 55.2% and 43.3% in the
ATG-F and control groups, respectively (p 5 0.39).
The following factors were analyzed with regard to OS, DFS,
risk of relapse, aGvHD III/IV, extensive cGvHD and NRM: pa-
tient age ([. /\ ] 40 y), donor age (. /\ ] 40 y), male patient/ fe-
male donor v. other, CMV negative v. seropositive, HLA-C
mismatch, type and status of disease, conditioning regimen (TBI
v. no TBI), source of stem cells (marrow v. PBSC), mean cyclospor-
ine trough levels during the first months (. /\median 220ng/ml),
graft cell count in PBSC (. /\ ] median 7.5x106 CD34/kg). In
multivariate analyses advanced disease was a negative factor for
aGvHD III-IV (HR 5 2.1, p 5 0.018), DFS (HR 1.7, p 5 0.004),
relapse (HR5 1.7, p 5 0.038), and OS (HR 5 1.9, p5 0.002). Pa-
tient age 40 years or more negatively affected NRM (HR5 1.8. p5
0.041). Interestingly, donor age 40 years or more adversely affected
the risk of aGvHD III-IV (HR5 2.6, p5 0.009), extensive cGvHD
(HR 5 2.1, p 5 0.021) and OS (HR 5 1.7, p 5 0.016), whereas
CMV status, male patient/female donor, HLA-Cmismatch, condi-
tioning, graft source, CD34 count or cyclosporine levels had no in-
fluence.
Conclusion: ATG-F significantly reduces acute and chronic
GvHD. By choosing younger donors outcome can be improved in
unrelated donor transplantation.32
ABROGATION OF DONOR T CELL IL-21 SIGNALING LEADS TO TISSUE-
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Interleukin 21 (IL-21) is a pro-inflammatory cytokine produced
by Th17 helper T cells, and abrogation of IL-21 signaling has re-
cently been shown to reduce GVHD while retaining GVL. How-
ever, mechanisms by which IL-21 may lead to a separation of
GVHD and GVL are incompletely understood. To characterize
its effect on GVH and GVL T cell responses, we compared
wild type (WT) and IL-21 receptor knockout (IL-21R KO) donor
T cells in a C57BL/6 into BALB/c murine MHC-mismatched
bone marrow transplant (BMT) model. Lethally irradiated BMT
recipients of IL-21R KO T cells demonstrated decreased
GVHD-related morbidity (p\ .05) and mortality (p\ .01) and
decreased histopathologic evidence of GVHD within the small
bowel (p\ .05). While this reduced GVHD was associated with
increased donor regulatory T cells two to three weeks post-
BMT (p \ .001), transplanting selected T cell subsets indicated
that IL-21 signaling in both donor CD4 and CD8 T cells contrib-
uted to GVHD mortality (CD4, p\ .01; CD8, p\ .05), although
effects on CD8 T cells occurred only in the presence of CD4s.
KO and WT donor T cells demonstrated equivalent alloactiva-
tion, as evidenced by proliferation (p \ .001), upregulation of
CD25 (p \ .001), and downregulation of CD62L (p \ .01 for
CD8 T cells) in allogeneic vs. syngeneic recipients. However,
IL-21R KO T cells demonstrated decreased infiltration within
the small bowel (p \ .05) and mesenteric lymph nodes (MLN;
CD8, p\ .05; CD4, p\ .001), and decreased inflammatory cyto-
kine-producing CD4 T cells within MLN (IFN-g, p\ .01; TNF-
a, p\ .001). Consistent with this, transplanted IL-21R KO donor
T cells demonstrated decreased expression of a4b7 integrin
(LPAM, p \ .05), a molecule known to be involved in homing
of GVHD-mediating donor T cells to the gut. However, in con-
trast to the reduced inflammatory cytokine-producing CD4 T
cells observed in MLN, IL-21R KO helper T cell cytokine pro-
duction was maintained in spleen and peripheral lymph nodes,
and IL-21R KO T cells were able to protect recipient mice
from lethality due to A20 lymphoma (p\ .001). In summary, ab-
rogation of IL-21 signaling in donor T cells leads to tissue-spe-
cific modulation of immunity, such that gastrointestinal GVHD
is reduced, but peripheral T cell function and GVL capacity are
retained. Targeting IL-21 for therapeutic intervention is an excit-
ing strategy to separate GVHD from GVL, and this novel ap-
proach should be considered for clinical investigation to
improve transplant outcomes and prevent malignant relapse.33
REG3a IS A BIOMARKER OF GRAFT VERSUS HOST DISEASE OF THE
GASTROINTESTINAL TRACT
Harris, A.C.1, Ferrara, J.L.M.1, Levine, J.E.1, Braun, T.1, Hogan, J.2,
Crawford, J.1, Pitteri, S.2, Wang, H.2, Chin, A.2, Zhang, Q.2,
Granger, J.1, Vander Lugt, M.1, Byersdorfer, C.1, Magenau, J.1,
Gomez, A.1, Choi, S.1, Kitko, C.1, Yanik, G.1, Peres, E.1,
Pawarode, A.1, Mineishi, S.1, Reddy, P.1, Couriel, D.R.1, Hanash, S.2,
Paczesny, S.1 1University of Michigan, Ann Arbor,MI; 2Fred Hutchinson
Cancer Research Center, Seattle, WA
There are no validated plasma biomarkers specific to graft versus
host disease (GVHD) of the gastrointestinal (GI) tract. We have pre-
viously identified and validated elafin as a plasma biomarker for skin
GVHD(ScienceTranslMed, 2:50-57).Using an unbiased proteomics
S164 Oral Presentationsdiscovery approach identical to that we employed for elafin, we first
analyzed plasma pooled from ten patients with and ten without GI
GVHD. We identified 164 candidate proteins that were increased
at least 1.5 fold, and two lead candidates, REG3a and CEACAM1,
were preferentially expressed in the GI tract and measurable by
ELISA. We then validated these two candidates in plasma from 570
BMT patients: 113 GI GVHD; 223 no GVHD; 52 non-GVHD
(e.g. infectious) enteritis; and 182 skin onlyGVHD.Groups were bal-
anced for age, myeloablative conditioning and sample collection. Un-
related and HLA-mismatched donors were over-represented in the
GVHD patient groups. REG3a levels were two to four fold higher
in the GI GVHD group compared to all others (mean6SEM in ng/
ml: 245640, 6468, 74618, 112622, respectively, p\ 0.004). The
area under the curve (AUC) of the receiver operating characteristic
(ROC) curve of GI GVHD with respect to non-GVHD enteritis
was 0.75 (95%CI, 0.66-0.82). Similar differences between patient
groups were seen with CEACAM1, but including CEACAM1 in
a composite ROC curve of both markers performed no better than
REG3a alone (AUC 5 0.75). Thus, subsequent analyses were per-
formed on REG3a. We divided patients with GI symptoms (n 5
165) into two equal groups based on the median concentration of
REG3a: low (\ 65 ng/ml, n 5 83) and high ($ 65 ng/ml, n 5 82).
The REG3ahigh group developed more severe GVHD, had higher
1year non-relapse mortality (NRM), and lower 1 year overall survival
(OS), than the REG3alow group (Table 1). KRT18 has previously
been reported as a marker for liver/GI GVHD (Blood, 114:702-
708); we measured its levels on the same patient samples and found
that while levels were significantly different in GI GVHD than in
non-GVHD enteritis (p5 0.01), they were not significantly different
between GI and Skin GVHD (p 5 0.5), and they did not correlate
with GVHD severity, NRM or OS (Table 1). We have identified
and validatedREG3a, aC-type lectinwhoseGI expression is increased
in response to inflammatory stimuli such as bacteria, mucosal damage
or inflammatory bowel disease (Science, 313:1126-1130), as a diagnos-
tic biomarker of GI GVHD with significant prognostic value.34
HIGH HERPESVIRUS-SPECIFIC T CELL COUNTS ARE ASSOCIATED WITH
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Introduction: Relapse is a major cause of hematopoietic cell trans-
plant (HCT) failure. Successful recovery of immunity against leuke-
mia treated with HCT (GVL immunity) is important in preventing
relapse. Thus, assays measuring GVL immunity could identify pa-
tients at risk of disease relapse. There is an association between re-
constitution of GVL immunity and herpesvirus specific immunity
(Parkman et al, BBMT 2006). Here we evaluated multiple assays
of anti-EBV/VZV/HHV6 immunity for their suitability to serve as
surrogates for GVL immunity and global antimicrobial immunity.
Patients &Methods:On day 56 post-transplant, we studied 46 allo-
HCT recipients for AML, who did not develop GVHD by day 56.
Blood mononuclear cells were stimulated with viral lysate from
EBV,HHV6 orVZV, or overlappingEBNA3, LMP112 orU54 pep-
tides, incubated overnight, stained for CD3, CD4, CD8, IFNg,
TNFa and IL2 and analyzed by flow cytometry. Patients were
followed for relapse and definite (microbiologically documented)Table 1. REG3a at onset of GI symptoms correlates with maximum
Maximum GVHD Grade
0 II-IV p-val
Low REG3a (%,95%CI) 45% (35%,55%) 55% (45%,65%) <0.0
High REG3a (%,95%CI) 17% (11%,27%) 83% (73%,89%)
Low KRT18 (%,95%CI) 34% (24%,45%) 66% (55%,76%) 0.5
High KRT18 (%,95%CI) 29% (20%,40%) 71% (60%,80%)infections. Absolute counts of each specific T cell subset were com-
pared between patients who did vs. did not relapse (or did vs. did
not develop at least one infection between day 56 and 180) using
Mann-Whitney test. Subsets with lowest p values were combined
into a scoring system, where for each subset, a score of 1 was assigned
to patients that had absolute counts above a cutoff, determined as the
mean between the highest value in patients who relapsed or developed
at least one infection and the nearest highest value.
Results:The following subset counts showed the highest association
with relapse: VZV specific CD4T cells producing IFNg, EBV lysate
specific CD8T cells producing IFNg and IL2, BZLF1 specific CD4
T cells producing IL2 with IFNg or TNFa, and BZLF1 specific T
cells producing TNFa and IL2. When the scores of these 5 subsets
were combined, a score of\1 was 100% sensitive and 78% specific
for relapse. The following subsets showed the highest association
with infections: U54 specific CD8 T cells producing TNFa,
EBNA3 specific CD4 T cells producing TNFa and IL2, and EBV
lysate specific CD8 T cells producing IFNg, TNFa and IL2. The
score of\ 1 was 100% sensitive and 36% specific for developing
at least one infection between day 56 and 180.
Conclusion: Herpesvirus specific T cell counts can serve as surro-
gates of both GVL immunity and global antimicrobial immunity.
They are highly sensitive but only moderately specific for relapse
and infections.35
CHARACTERIZING BIDIRECTIONAL INTERACTIONS BETWEEN THE
INTESTINAL FLORA AND GRAFT-VERSUS-HOST DISEASE
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Our immune system interacts dynamically with our microbial
flora. Perturbing this balance can lead to pathological inflammation.
Prior animal and clinical studies of allogeneic hematopoietic stem
cell transplantation (HSCT) suggest that variations in gut flora can
predispose or protect against graft-versus-host disease (GVHD).
Gut decontamination as GVHD prophylaxis, however, gave mixed
results, and our knowledge of the gut microbiota was limited to
the 20-30% of species that can be cultured. Novel methodology, in-
cluding 16s ribosomal DNA sequencing, allows more complete
characterization of the gut flora. We thus revisited whether manip-
ulation of gut flora can minimize GVHD.
We used a MHC-disparate B10BR/B6 mouse model for allo-
HSCT and found that GVHD leads to changes in gut flora, particu-
larly in the distal ileum. Shifts in representationbybacterial families re-
sult in a nearly complete takeover by Lactobacillaceae and loss of
several familiesofFirmicutes (Table).These changes are readily repro-
ducible, includingwith individually-housedmice. This pattern of flora
associated with GVHD was distinct from patterns found in control
groups: HSCT recipients without GVHD, mice with dextran sulfate
sodium-induced colitis, and mice treated with osmotic laxatives.
Potential mechanisms behind this characteristic GVHD-associ-
ated flora are continuing to be explored, but thus far do not appear
to be due to changes in numbers of Paneth cells, expression of
IL22 or the antimicrobial molecule Reg3g, or luminal levels of
IgA. Interestingly, the bacterial density in the ileum, quantified by
copies of 16s rDNA, is similar in mice with or without GVHD after
HSCT, and is twice that of untreated mice.
We then performed experiments evaluating flora manipulation
prior to HSCT. We found that ampicillin treatment followed by
a 2 week recovery results in complete loss of Lactobacillaceae andGVHD grade, 1 year NRM and 1 year OS
ue 1 year NRM p-value 1 year OS p-value
01 24% (15%,35%) <0.001 68% (58%,79%) 0.001
49% (38%,60%) 43% (33%,56%)
4 39% (29%,51%) 0.9 57% (47%,69%) 0.22
33% (23%,44%) 54% (44%,66%)
